ERBB2 and breast cancer: Finally, considering that ongoing studies may demonstrate the activity of ADCs in earlier lines of therapy, it is possible that these agents will further challenge the sequence of available treatments, as well as the current algorithm in HR+, HER2-negative breast cancer.